Which act allows labeling stating that safety and effectiveness in pediatric patients have not been established on drugs with insufficient evidence to support pediatric indications?

Which act allows labeling stating that safety and effectiveness in pediatric patients have not been established on drugs with insufficient evidence to support pediatric indications?

• A. The Food and Drug Administration Modernization Act (FDAMA)
• B. The Pediatric Research Equity Act (PREA)
• C. The Best Pharmaceuticals for Children Act (BPCA)
• D. The Prescription Drug User Fee Act (PDUFA)

Answer: (A)

The main idea here is how labeling communicates what we know about using a drug in children. The FDA Modernization Act of 1997 gave the FDA the authority to address pediatric information in labeling, including language that clearly states when there is not enough data to establish safety and effectiveness for pediatric use. If the evidence is insufficient to support pediatric indications, the label can say that safety and effectiveness in pediatric patients have not been established. This helps clinicians avoid assuming that adult data automatically apply to children and makes explicit any gaps in pediatric evidence. The other acts concentrate on encouraging or funding pediatric research (to generate data) or on changing the drug-approval process, rather than on the labeling statement itself. Pediatric Research Equity Act requires pediatric studies for new drugs; Best Pharmaceuticals for Children Act provides incentives to study in children; and the Prescription Drug User Fee Act deals with FDA funding. While these influence what data exist, they do not specifically mandate the labeling phrasing about lack of pediatric data in the same way FDAMA does.

The main idea here is how labeling communicates what we know about using a drug in children. The FDA Modernization Act of 1997 gave the FDA the authority to address pediatric information in labeling, including language that clearly states when there is not enough data to establish safety and effectiveness for pediatric use. If the evidence is insufficient to support pediatric indications, the label can say that safety and effectiveness in pediatric patients have not been established. This helps clinicians avoid assuming that adult data automatically apply to children and makes explicit any gaps in pediatric evidence.

The other acts concentrate on encouraging or funding pediatric research (to generate data) or on changing the drug-approval process, rather than on the labeling statement itself. Pediatric Research Equity Act requires pediatric studies for new drugs; Best Pharmaceuticals for Children Act provides incentives to study in children; and the Prescription Drug User Fee Act deals with FDA funding. While these influence what data exist, they do not specifically mandate the labeling phrasing about lack of pediatric data in the same way FDAMA does.